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Studies of the major psychoses, schizophrenia (SZ) and bipolar disorder (BD), have traditionally focused on
genetic and environmental risk factors, although more recent work has highlighted an additional role for epi-
genetic processes in mediating susceptibility. Since monozygotic (MZ) twins share a common DNA se-
quence, their study represents an ideal design for investigating the contribution of epigenetic factors to
disease etiology. We performed a genome-wide analysis of DNA methylation on peripheral blood DNA sam-
ples obtained from a unique sample of MZ twin pairs discordant for major psychosis. Numerous loci demon-
strated disease-associated DNA methylation differences between twins discordant for SZ and BD
individually, and together as a combined major psychosis group. Pathway analysis of our top loci highlighted
a significant enrichment of epigenetic changes in biological networks and pathways directly relevant to psy-
chiatric disorder and neurodevelopment. The top psychosis-associated, differentially methylated region, sig-
nificantly hypomethylated in affected twins, was located in the promoter of ST6GALNAC1 overlapping a
previously reported rare genomic duplication observed in SZ. The mean DNA methylation difference at this
locus was 6%, but there was considerable heterogeneity between families, with some twin pairs showing a
20% difference in methylation. We subsequently assessed this region in an independent sample of post-
mortem brain tissue from affected individuals and controls, finding marked hypomethylation (>25%) in a
subset of psychosis patients. Overall, our data provide further evidence to support a role for DNA methylation
differences in mediating phenotypic differences between MZ twins and in the etiology of both SZ and BD.
INTRODUCTION
Schizophrenia (SZ) and bipolar disorder (BD) are two related
psychiatric conditions that together contribute significantly to
the global burden of disease (1). SZ is defined primarily by the
presence of psychotic symptoms, and is also characterized by
dysfunctional affective responses and altered cognition. BD
presents with episodic swings in mood, potentially ranging
from extreme mania to severe depression, and is often accom-
panied by psychotic symptoms and impaired cognition. This
overlap between the symptoms of SZ and BD, which can be
classified together as ‘major psychosis’, suggests there may
be etiological factors common to both disorders (2,3).
SZ and BD clearly aggregate in families, and quantitative
genetic analyses highlight a strong inherited component to
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both. However, although heritability is estimated to be 70%
(4,5), disease concordance within monozygotic (MZ) twin
pairs is far from 100% (6,7), indicating that non-genetic
factors are also important in the etiology of the diseases. Re-
cently, increasing emphasis has been placed on the potential
role of epigenetic dysfunction in the etiology of psychosis (8).
Epigenetic mechanisms mediate mitotically heritable, but re-
versible, changes in gene expression without changing the
genomic DNA sequence, principally through alterations in
DNA methylation and chromatin structure (9). Epigenetic
changes in the brain have been associated with a range of bio-
logical and cognitive processes including neurogenesis (10),
brain growth and development (11), learning and memory
(12), drug addiction (13), neurodegeneration (14) and circadian
rhythm (15). It has been widely speculated that epigenetic dys-
function in the brain may be involved in a spectrum of psychi-
atric disorders including psychosis (16,17). Although
epigenetic studies in psychiatric disorders are in their infancy,
a recent postmortem brain study of patients with psychosis
and healthy controls uncovered significant epigenetic changes
associated with both SZ and BD across the genome (18).
Investigating discordant MZ twin pairs is a powerful strat-
egy for uncovering disease-associated epigenetic changes
because it allows an assessment of the epigenome independent
of any underlying genomic sequence variation (19). Recent
studies have uncovered a large amount of DNA methylation
variability between MZ twins (20,21), supporting the notion
that epigenetic variation may contribute to phenotypic discord-
ance between genetically identical individuals. The utility of
disease-discordant twins in epigenetic epidemiological
studies of complex disease was highlighted by a recent ana-
lysis of DNA methylation differences between MZ twins dis-
cordant for systemic lupus erythematosus (22). To date, few
studies have empirically tested for epigenetic differences
between MZ twins discordant for neuropsychiatric disorders
and none has looked genome-wide across a large number of
twin pairs. Petronis et al. (23) found evidence for DNA methy-
lation differences in the promoter of DRD2 in one
SZ-discordant MZ twin pair. Kuratomi et al. (24) examined
two pairs discordant for BD and found increased methylation
in affected twins upstream of the spermine synthase gene
(SMS) and decreased methylation upstream of the peptidylpro-
lyl isomerase E-like gene (PPIEL). Rosa et al. (25) assessed
skewed X-chromosome inactivation in 63 female MZ twin
pairs with mixed concordance for BD or SZ, reporting that dis-
cordant female BD twins showed greater differences in the
methylation of the maternal and paternal chromosome X
alleles than concordant twin pairs.
In this study, we report the first systematic genome-wide
analysis of DNA methylation differences between MZ twins
discordant for SZ and BD, using whole-blood DNA obtained
from a unique collection of twins. We found numerous
disease-associated differences in DNA methylation, many
located in the vicinity of genes previously implicated in psych-
osis. Our data support the hypothesis that epigenetic altera-
tions play an important role in the etiology of SZ and BD.
RESULTS
Overview of experimental strategy
Genome-wide DNA methylation was measured in a unique
collection of 22 twin pairs (44 individuals) discordant for SZ
or BD, using the Illumina Infinium HumanMethylation27
BeadChip. Demographic data for the samples included in
this study are given in Table 1 and Supplementary Material,
Table S1. We used an analytical approach that took advantage
of the discordant MZ twin design and tested both the magni-
tude of differences and significance to maximize our
chances of identifying real within-twin differences in DNA
methylation associated with SZ, BD and a combined ‘psych-
osis’ diagnosis. Furthermore, given the known phenotypic het-
erogeneity of both SZ and BD, we screened for large DNA
methylation differences within each discordant MZ twin pair
to examine the possibility that disease-associated epigenetic
changes are not consistent across all patients. The top-ranked
disease-associated probe was verified in the same samples,
using the Sequenom EpiTYPER platform, and then tested in
a set of 45 postmortem brain samples from patients and un-
affected controls. Full experimental details are given in
Materials and Methods.
Genome-wide DNA methylation analysis
Genome-wide DNA methylation was measured in 22 twin
pairs (44 individuals) discordant for SZ or BD, using the Illu-
mina Infinium HumanMethylation27 BeadChip. Demographic
data for the samples included in this study are given in Table 1
and Supplementary Material, Table S1. All arrays passed
standard quality control metrics and were included in our
analyses. As expected, there was a high correlation in genome-
wide DNA methylation within each MZ twin pair (Supple-
mentary Material, Fig. S1), indicating no systemic changes
in genome-wide epigenetic programming. The mean within-
pair correlation (r2) was 0.99 across all analyzed probes on
the array and 0.96 across all ‘variable’ probes (i.e. excluding
those with a probe-wise standard deviation smaller than the
estimated standard deviation across all probes on the array).
This concurred with the results of our LINE-1 element pyrose-
quencing assay (Supplementary Material, Fig. S2), which
Table 1. Demographic details for the discordant MZ twin-pair samples utilized in this study
SZ-discordant twin pairs BD-discordant twin pairs Psychosis (SZ and BD)-discordant twin pairs
Sex (males:females) 8:3 2:9 10:12
Ethnicity 10 Caucasian, 1 unknown 10 Caucasian, 1 Afro-Caribbean 20 Caucasian, 1 unknown, 1 Afro-Caribbean
Time discordant (years) 10.4+ 10.6 14.6+ 10.7 12.6+ 10.6
Age of onset (years) 20.0+ 4.6 21.7+ 12.3 20.9+ 9.3
Values shown are mean+ standard deviation.
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identified no significant differences in global DNA methyla-
tion between affected and unaffected twins for either SZ or
BD (SZ-discordant twins: affected-twin mean ¼ 85%,
unaffected-twin mean ¼ 86%, P ¼ 0.28; BD-discordant
twins: affected-twin mean ¼ 85%, unaffected-twin mean ¼
86%, P ¼ 0.38).
In contrast, DNA methylation at individual CpG sites
showed considerable variability within MZ twin pairs (Fig. 1
and Supplementary Material, Figs S3 and S4). Using an ana-
lysis method designed to identify the largest and most signifi-
cant differences in DNA methylation at specific CpG sites, we
identified numerous sites throughout the genome exhibiting
disease-associated differential DNA methylation (Figs 1, 2
and Supplementary Material, Fig. S4). Table 2 shows the
genes located nearest to the eight top-ranking
disease-associated, differentially methylated CpG sites in
each of the three diagnostic analysis groups: SZ, BD and a
combined psychosis group. Supplementary Material, Tables
S2–S4 show the top 100 differentially methylated CpG sites
for each group. The full methylation data set for all CpG
sites analyzed in this study is available for download from
our laboratory website (http://epigenetics.iop.kcl.ac.uk/p
sychosis). Of note, analysis of the location of the 100
top-ranked psychosis-associated, differentially methylated
CpG sites demonstrates a significant under-representation of
CpG sites located within CpG islands (62% versus 76% for
all probes on the Illumina 27K array, x2 P, 0.001).
Overall, the top differentially methylated site across all 22
psychosis-discordant MZ twin pairs was located in the
promoter region of the gene encoding alpha-N-acetylgalacto
saminide alpha-2,6-sialyltransferase 1 (ST6GALNAC1),
which was hypomethylated in affected individuals compared
with their unaffected co-twins (mean Db ¼ 0.06, P ¼ 4.03E
2 04). The top differentially methylated CpG site across the
discordant SZ twin pairs was located upstream of the gene
encoding pseudouridylate synthase 3 (PUS3), being
hypermethylated in affected twins (mean Db ¼ 20.07,
P ¼ 7.66E 2 04). The top-ranked CpG site across the discord-
ant BD MZ twin pairs resided upstream of the gene encoding
melanin-concentrating hormone receptor 1 (GPR24), which
was hypomethylated in affected twins (mean Db ¼ 0.07,
P ¼ 1.3E 2 03). Twin-pair-specific DNA methylation differ-
ences for the top-ranked CpG sites for each analysis group
are shown in Figure 2 and Supplementary Material, Figure S5.
Although the direction of effect for the top-ranked loci is
consistent across individual pairs within each diagnostic
group, some loci show variation in the degree of methylation
differences between affected and unaffected twins, indicating
that there is inter-family heterogeneity even within our
top-ranked loci. Our top-ranked psychosis differentially
methylated site in the promoter of ST6GALNAC1, for instance,
showed a spectrum of within-twin Db-values up to 0.20
(Fig. 2A). Given the clinical heterogeneity of psychosis, it is
widely hypothesized that there are rare etiological factors of
large effect (e.g. copy-number variation) (26) underlying
some cases, and it is plausible that individual twin pairs may
similarly harbor large methylation differences at specific
disease-associated loci. We therefore assessed DNA methyla-
tion differences separately within individual twin pairs to look
for the largest family-specific alterations. An example of the
differences within one representative discordant MZ twin
pair is given in Supplementary Material, Figure S3, with
data for the full set of twins available for download from
our laboratory webpage (http://epigenetics.iop.kcl.ac.uk/p
sychosis). A number of novel and known psychiatric candidate
genes showed large DNA methylation differences between
members of one or a few twin pairs, with some loci showing
a Db-value .0.60 between the affected and unaffected twin.
Figure 1. Idiogram illustrating the mean DNA methylation difference (Db-value) (well-twin minus ill-twin) for each CpG site included in our analysis across all
22 pairs of psychosis-discordant MZ twins. The red-colored dots correspond to the 100 top-ranked CpG sites (Supplementary Material, Table S3). Similar idio-
grams for SZ- and BD-discordant twins-pairs are shown in Supplementary Material, Figure S4.
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A full list of CpG probes showing a Db. 0.30 within each in-
dividual twin pair is given in Supplementary Material,
Table S5.
Intriguingly, some CpG sites ranked highly in both the ana-
lysis of the SZ-discordant and BD-discordant twins, but with
opposite changes in DNA methylation between disorders, indi-
cating that some epigenetic changes may be disorder-specific.
Of note, a CpG site in the promoter of ZNF659 (cg18267381),
ranking in the 100 top-ranked loci in both the discordant SZ
and BD MZ twin pairs, was hypomethylated in the BD
twins [average Db ¼ 0.04, (P , 0.005)] but hypermethylated
[average Db ¼ 20.06 (P , 0.01)] in the SZ twins (Fig. 3).
Interestingly, a number of other probes in the 100 top-ranked
SZ and BD loci show nominally-significant b differences in
the opposite direction in the alternative diagnostic group (Sup-
plementary Material, Fig. S6).
Analyses were performed to assess correlation between
DNA methylation and ‘time discordant’, with no significantly
correlated loci suggesting that the twins are not becoming
more epigenetically different over the course of their illness.
Given recent reports of a correlation between age and DNA
methylation at specific loci (27,28), we also investigated the
effects of age on the data. Including age as a covariate in
our analyses made little change to the list of top-ranked loci.
Intriguingly, however, we did replicate several of the previ-
ously reported correlations between age and DNA methylation
in our twin data (Pidsley et al., in preparation), supporting the
notion that DNA methylation changes dynamically through
life and affirming the reproducibility of data generated using
the Illumina array platform across studies.
Verification and replication of disease-associated
hypomethylation at ST6GALNAC1
Our Sequenom EpiTYPER data exactly replicated the array
data at the specific CpG site represented on the Illumina plat-
form (cg13015534), demonstrating hypomethylation in
affected psychosis twins (psychosis twin average ¼ 35%
methylation, unaffected twin ¼ 41% methylation). Interesting-
ly, the verification data on the SZ twins highlighted an even
larger difference (average 15% hypomethylation) in DNA
methylation between the affected and unaffected twins than
that was detected on the array at this site. Further validation
of disease-associated DNA methylation at ST6GALNAC1
was performed on postmortem brain samples from the
Stanley Foundation Neuropathology Consortium. Overall
levels of DNA methylation in the brain were higher (85%)
than those observed in the blood (40%, from both raw Illu-
mina array data and Sequenom EpiTYPER data). Although no
overall significant difference in DNA methylation at the array-
nominated site (CpG4 in the Sequenom assay) was observed
between psychosis cases and controls, it was striking that 4
out of the 30 (13.3%) psychosis cases tested showed marked
(up to 27%) hypomethylation and were clear outliers at this
CpG, and several adjacent CpG sites (Fig. 4). No such hypo-
methylation of the ST6GALNAC1 promoter was observed in
any control samples, which showed a consistently tight methy-
lation profile across the region. These brain data reflect the sig-
nificant heterogeneity between twin pairs seen in the blood
data (Fig. 1), where some affected siblings demonstrated up
to 20% hypomethylation but other twin pairs showed much
Table 2. The top eight differentially methylated CpG sites for each of the three diagnostic analysis groups, ranked by a combination of both mean Db (well-twin
minus ill-twin) and statistical significance
Analysis group Rank Gene name Chromosome Paired t-test P-value Mean Db (minimum–maximum) Weighted Db P-value Weighted q-value
Psychosis 1 ST6GALNAC1 17q25.1 4.03E2 04 0.06 (20.11–0.20) 1.19E2 07 7.97E2 04
2 ACADL 2q34 2.49E2 04 0.05 (20.05–0.17) 1.59E2 06 3.19E2 03
3 TBC1D10A 22q12.2 8.56E2 04 0.06 (20.05–0.23) 9.40E2 08 7.97E2 04
4 PUS3 11q24.2 7.66E2 04 20.05 (20.16–0.06) 1.71E2 06 3.19E2 03
5 FXR2 17p13.1 1.74E2 03 0.06 (20.09–0.26) 9.03E2 08 7.97E2 04
6 TSP50 3p21.31 4.92E2 04 0.04 (20.05–0.12) 2.26E2 05 1.12E2 02
7 PCOLN3 16q24.3 1.27E2 03 0.04 (20.06–0.21) 1.79E2 05 1.03E2 02
8 SOX1 13q34 1.04E2 03 0.04 (20.04–0.13) 2.64E2 05 1.18E2 02
SZ 1 PUS3 11q24.2 7.66E2 04 20.07 (20.16–0.03) 5.16E2 05 0.10
2 SYNGR2 17q25.3 8.29E2 04 0.07 (0.01–0.13) 9.82E2 05 0.14
3 KDELR1 19q13.3 1.25E2 03 20.06 (20.14–0.01) 3.07E2 04 0.18
4 PDK3 Xp22.11 7.54E2 04 0.06 (0.00–0.14) 3.67E2 04 0.18
5 PPARGC1A 4p15.1 1.85E2 03 0.06 (20.02–0.12) 2.89E2 04 0.18
6 ACADL 2q34 3.74E2 03 0.07 (0.00–0.17) 7.81E2 05 0.12
7 FLJ90650 5q23.1 4.19E2 04 0.05 (20.01–0.09) 6.98E2 04 0.19
8 TUBB6 18p11.21 3.54E2 03 0.06 (20.01–0.18) 1.78E2 04 0.16
BD 1 GPR24 22q13.2 1.30E2 03 0.07 (0.00–0.16) 7.59E2 05 0.17
2 TLE6 19p13.3 1.97E2 03 20.09 (20.21–0.01) 1.54E2 05 0.12
3 STAB1 3p21.1 1.63E2 03 20.07 (20.18–0.02) 8.11E2 05 0.17
4 PPYR1 10q11.2 5.13E2 04 20.06 (20.12–0.01) 3.44E2 04 0.25
5 CTNNA2 2p12 3.59E2 03 0.09 (0.00–0.21) 1.56E2 05 0.12
6 ST6GALNAC1 17q25.1 3.06E2 03 0.06 (20.01–0.15) 2.82E2 04 0.23
7 C1orf35 1q42.13 5.30E2 03 0.06 (20.01–0.18) 1.88E2 04 0.23
8 IQCH 15q23 3.94E2 03 0.05 (20.06–0.10) 7.81E2 04 0.30
The top 100 ranked differentially methylated CpG sites for each diagnostic analysis group are given in Supplementary Material, Tables S2–S4, and data for all
CpG sites included in our analyses are available for download from our laboratory website (http://epigenetics.iop.kcl.ac.uk/psychosis).
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smaller differences. Together, these data indicate that large
disease-associated changes at this locus may affect a small
number of patients.
Ingenuity pathway analysis
We performed ingenuity pathway analysis (IPA) on the 100
top-ranked loci from the analysis of MZ twins discordant for
SZ and BD (listed in Supplementary Material, Tables S2–
S4) to examine whether common networks or pathways
were over-represented in the list of genes associated with the
top differentially methylated CpG sites for each disorder.
Strikingly, core IPA analysis revealed strong enrichment for
phenotypically relevant gene networks: the top scoring func-
tional network in the SZ gene list was ‘nervous system devel-
opment and function’, and in the BD gene list the top network
was ‘developmental, genetic and neurological disorder’ fol-
lowed by a network related to ‘psychological disorders’
(Table 3). The top biological function pathway in the SZ
gene list was ‘psychological disorders’, comprising nine
genes directly implicated in SZ (CCND2, CHRNA2, FXR2,
FXYD6, HRH3, MUC1, PFN2, SLC31A2, SLC6A3) (P ¼
3.64E2 03). The first and third canonical pathways were
dopamine receptor signaling (P ¼ 6.08E 2 03) and glutamate
receptor signaling (P ¼ 3.31E2 02), respectively. Further-
more ‘nervous system development and function’ was the
top ranking function within ‘physiological system develop-
ment and function’ from the BD gene list (P ¼ 1.07E2 03–
4.85E2 0.2) and third highest from the SZ gene list (P ¼
7.83E2 0.5–3.45E2 0.2). These results are presented in
Supplementary Material, Tables S6–S9.
DISCUSSION
This study represents the first comprehensive analysis of
disease-associated DNA methylation differences in MZ
twins discordant for SZ and BD, using a genome-wide ap-
proach. We found no alterations in global DNA methylation
between affected and unaffected twins, but considerable
disease-associated between-twin differences at specific loci
across the genome. Some differences were consistently
altered across a combined discordant psychosis group,
whereas others appear to be specific to either SZ or BD. Fur-
thermore, although many differences were identified across all
discordant twin pairs for each diagnostic category, others were
specific to one or a couple of pairs. Our hypothesis-free ex-
perimental design allowed us to identify disease-associated
DNA methylation differences at loci not previously implicated
in psychiatric disorders, but we also found evidence for DNA
methylation differences at genes previously implicated in
psychosis, such as GPR24 and CTNNA2 in BD. Pathway ana-
lysis of our top loci highlighted a significant enrichment of
epigenetic disruption to biological networks and pathways
relevant to psychiatric disease and neurodevelopment.
Overall, our data provide further evidence to support a role
for DNA methylation differences in the etiology of both SZ
and BD.
The overall top-ranked psychosis-associated methylation
difference identified in this study was at a CpG site in the pro-
moter of ST6GALNAC1, located at 17q25.1, which we found
was hypomethylated in affected twins. Interestingly, we also
found that .13% of postmortem brain samples from SZ and
BD patients tested showed marked hypomethylation over an
extended region encompassing the nominated CpG site,
Figure 2. DNA methylation differences (Db-value) (well-twin minus ill-twin) for the top-ranked probes from (A) the combined psychosis-discordant analysis
group: ST6GALNAC1 (cg13015534), (B) SZ-discordant analysis group: PUS3 (cg02659232) and (C) the BD-discordant analysis group: GPR24 (cg21342728).
Psychosis ¼ twin pairs 1–22, SZ ¼ twin pairs 1–11, BD ¼ twin pairs 12–22.
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suggesting that epigenetic changes at this region may be
present in a subset of psychosis patients. The
psychosis-associated CpG site does not reside in a CpG
island, reflecting the observation that our top
disease-associated, differentially methylated loci are signifi-
cantly under-represented for classical CpG-rich promoters
and concurring with data from recent epigenomic profiling
studies showing that phenotypically relevant variation in
DNA methylation often occurs outside of such regions (29).
ST6GALNAC1 is a member of the sialyltransferease family of
molecules, involved in protein glycosylation, with a key role in
mediating cell–cell interactions. ST6GALNAC1 is expressed in
the brain and other CNS tissue and is differentially regulated
during key periods of neurodevelopment (30). We performed
in silico analysis of the specific CpG site (cg13015534) nomi-
nated in our study, using publicly available ENCODE
ChIP-seq data in the UCSC genome browser (http://genome.
ucsc.edu/) (Supplementary Material, Fig. S7). The site lies dir-
ectly proximal to a peak of Pol2 occupancy and within a
region able to bind neuron restrictive silencer factor/
RE1-silencing transcription factor (NSRF/REST), a key regula-
tor of neuronal differentiation that acts to silence neuronal genes
in non-neuronal tissue (31). ENCODE DNA methylation data
generated using the Illumina 27K array shows that DNAmethy-
lation at cg13015534 is inversely correlated with Pol2 binding
and ST6GALNAC1 expression, suggesting that variation in
methylation at this locus is directly associated with gene tran-
scription and function. Interestingly, a rare inherited genomic
duplication spanning the gene, including the disease-associated
CpG identified in this study, was reported recently in a single
case of SZ (32), suggesting that over-expression of the gene
may be implicated in pathogenesis. Given that promoter hypo-
methylation is typically associated with increased gene expres-
sion, a disease-associated duplication of ST6GALNAC1 is
consistent with our data. Hypermethylation at this locus has
also been associated with estrogen and progesterone receptor-
positive breast cancers (33), highlighting that epigenetic
variation in the ST6GALNAC1 promoter has important pheno-
typic consequences that may well be pleiotropic. Finally,
another member of the sialyltransferease family of molecules,
sialyltransferease 8B (SIAT8B), has been previously associated
with SZ (34) and animal studies indicate that ablation of this
gene leads to incomplete polysialylation of the neuronal cell ad-
hesionmolecule causing severe defects in the anatomical organ-
ization of the forebrain (35), which potentially provides a direct
mechanism for the role of this gene in the predisposition to SZ.
A number of the other top-ranked genes nominated by our
study have been previously implicated in SZ and BD. For
example, animal models and human genetic studies suggest
that GPR24 (22q13.2), encoding G protein-coupled receptor
24, is involved in the susceptibility to BD. GPR24 knock-out
animals show dysregulation of the mesolimbic dopamine
system (36), a key system in psychosis. Furthermore, GPR24
antagonists have antidepressant and anxiolytic effects, impli-
cating this gene in the regulation of mood (37,38). There is
also genetic evidence to suggest a direct involvement of
GPR24 in psychosis; it lies within one of the strongest
linkage peaks nominated by a comprehensive meta-analysis
(39), and polymorphisms in the gene have been associated
with both BD and SZ (40). Interestingly, our significant
CpG site is located only 21 bp from rs133073 (although not
overlapping the probe), one of the SNPs strongly associated
with psychosis.
The alpha catenin gene (CTNNA2) is located in an SZ
linkage region 2p11 (41), and encodes a neuronal
cadherin-associated protein that plays a major role in folding
and lamination of the cerebral cortex (42). This gene has
been previously identified as a susceptibility gene in a
genome-wide association study and meta-analysis of BD com-
prising 3683 cases and 14 507 controls (43). Furthermore,
polymorphisms in LRRTM1, a gene residing in an intron of
CTNNA2, have been associated with psychosis in a
parental-origin-specific manner (44). Schalkwyk et al. (45)
found evidence for allele-specific methylation in this region
Figure 3. DNA methylation differences (Db-value) (well-twin minus ill-twin) for a CpG site located at ZNF659 (cg18267381), which shows disease-associated
hypermethylation in SZ (twin pairs 1–11, blue bars) but disease-associated hypomethylation in BD (twin pairs 12–22, red bars).
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supporting the theory that this region could be imprinted and
mediating risk via an interaction between genetic and epigen-
etic factors.
Previous studies investigating MZ-discordant pairs for
psychosis have been limited to one or a few twin pairs. One
strength of our study is that by using DNA samples from 22
discordant MZ twin pairs, representing one of the largest
twin studies performed for any complex disease phenotype
to date, we were also able to identify DNA methylation differ-
ences that are consistently changed across multiple discordant
MZ twin pairs in addition to identifying family-specific
disease-associated epigenetic changes. The only other
large-scale genome-wide study of DNA methylation changes
associated with psychosis investigated postmortem brains
from patients and controls and found a number of highly sig-
nificant alterations in DNA methylation (18). Interestingly five
of our top 100 ranked genes overlap with those found to be
significantly associated with psychosis in that study—GGN,
SLC117A, SMUG1, SOX1 and TCF7L2 (Supplementary Ma-
terial, Table S10)—suggesting that epigenetic variation at
these loci deserves further investigation. Individual twin pair
analysis in our study also highlighted considerable familial
heterogeneity, with some pairs showing much greater disparity
in DNA methylation at certain loci. Furthermore, we observed
some large methylation changes that were specific to one or a
few twin pairs (Supplementary Material, Table S5), suggesting
that some rare epigenetic alterations of large effect may be
associated with psychosis.
Our study has a number of limitations that should be consid-
ered when interpreting the data presented here. First, although
this represents the largest disease-discordant MZ twin study to
date for any complex psychiatric disorder, our analysis was
limited to only 22 pairs of twins. A power calculation based
on an estimate of the standard deviation of the whole data set
from the Illumina array data shows that, at a stringent
Bonferroni-corrected P-value cut-off (1.86E 2 06), our
sample of 22 discordant MZ pairs gives good power (.80%)
to detect a Db of 0.06, although the power to detect smaller dif-
ferences at this level of significance is more limited, as are ana-
lyses in the diagnostic subgroups. It is noteworthy that using our
weighted t-test based on the magnitude of change observed
between affected and unaffected twins at each locus, many of
our top-ranked loci are highly significant, with FDR values
(q-values) ,0.05. The significant over-enrichment of biologic-
ally relevant pathways in our IPA network analyses of
top-ranked loci adds further weight to the power of our study
to uncover valid differences. Because the discordant MZ-twin
design is such a powerful tool for identifying epigenetic vari-
ation associated with phenotype (19), a notion affirmed by our
success in identifying disease-associated epigenetic changes,
future efforts should focus on collecting biological material
from additional twin pairs for use in methylomic analyses.
Second, by necessity, this study was performed on DNA
samples extracted from peripheral blood rather than from the
brain. To our knowledge, there is no archived collection of
postmortem MZ twin brains discordant for psychosis. Al-
though the epigenome clearly shows tissue-specific patterns,
there is mounting evidence from other disorders that
disease-associated epimutations may be detectable across
tissues (46,47). Our own methylomic profiling across the
brain and blood from multiple individuals shows that although
tissue-specific variation far outweighs between-individual
variation, many between-individual differences are observed
across tissues (unpublished data, see http://epigenetics.iop.
kcl.ac.uk/brain). In this regard, it is reassuring that we find
evidence for disease-associated hypomethylation of the
ST6GALNAC1 promoter in postmortem brain tissue from
Figure 4. DNA methylation across multiple CpG sites in the promoter of
ST6GALNAC1 in postmortem brain tissue from psychosis patients and con-
trols. Postmortem brain tissue from affected individuals showed no overall sig-
nificant hypomethylation, but 4 out of the 30 (13.3%) psychosis cases tested
showed marked (up to 27%) hypomethylation at the same CpG site nominated
from the array analysis, with hypomethylation extending across several adja-
cent CpG sites. No such hypomethylation was observed in any unaffected
control samples which all demonstrated very similar methylation values
(shown is mean control sample methylation; error bars denote standard
deviation).
Table 3. The top-scoring functional networks of genes nominated by analysis
of SZ-discordant twin pairs and BD-discordant twin pairs
Associated network functions Network
score
Top SZ networks
1 Nervous system development and function, cellular
development, reproductive system development and
function
73
2 Cell signaling, nucleic acid metabolism, small-molecule
biochemistry
39
3 Embryonic development, organ development, organ
morphology
30
Top BD networks
1 Neurological disease, developmental disorder, genetic
disorder
67
2 Psychological disorders, genetic disorder, nutritional disease 48
3 Gene expression, RNA post-transcriptional modification,
organismal development
18
The network score is a numerical value used to rank networks according to their
degree of relevance to the network eligible molecules in the gene list. A number
of functional networks directly related to psychosis were highlighted by these
analyses.
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affected patients, and that some of the genes nominated from a
previous study on brain samples were also in our list of
top-ranked loci (Supplementary Material, Table S10). Further-
more, our IPA data demonstrates that we can clearly identify
epigenetic changes to disease-relevant pathways from periph-
eral samples. A recent study by Kaminsky et al. (48) found
BD-associated methylation changes in the promoter of
HCG9 in both brain and peripheral samples, and other
reports have also successfully used peripheral tissues to iden-
tify disease-associated epigenetic changes in psychosis
(24,49). Finally, the use of peripheral samples may have
some advantages over the use of the brain; sample collection
is more standardized between twins and is not subject to po-
tential confounding issues such as postmortem delay (8).
Third, it is hard to draw conclusions about causality for any
of the differentially methylated regions identified in our study,
in part because we do not have DNA samples from the twins
taken before they became discordant for disease. It is plausible
that many of the changes we identify have occurred down-
stream of the disease, resulting from exposure to antipsychotic
medication, for example. There is mounting evidence that
many of the drugs used to treat both SZ and BD induce epi-
genetic changes (50). Such changes are interesting, however,
and understanding the pathways via which these drugs work
may provide information about the neurobiological processes
involved in disease. The ideal study design would be to longi-
tudinally assess DNA methylation changes in the brain during
an individual’s’ transition into disease, although such a study
is clearly unfeasible at present.
Finally, although the microarray platform utilized in this
study (the Illumina 27K Methylation Array) is reliable and
has been previously used to identify quantitative changes in
DNA methylation (51), it is relatively limited in the density
of probe coverage, interrogating only a couple of CpG sites
for the majority of genes with a bias to loci implicated in
cancer. This actually makes the results of our pathway analysis
more striking, given the clear over-representation of DMRs
related to neurobiological processes. Future work should
build on the recent technological advances in methylomic pro-
filing and examine DNA methylation differences between dis-
cordant twins at much higher resolution.
To conclude, we have undertaken the first large-scale ana-
lysis of disease-associated epigenetic changes in MZ twins
discordant for major psychosis identifying numerous DNA
methylation differences associated with both SZ and BD.
These findings further support the notion that epigenetic pro-
cesses probably play an important role in neuropsychiatric
disease and highlight the power of the discordant MZ twin
design for epigenomic studies of complex disease.
MATERIALS AND METHODS
Samples
Genomic DNA was extracted using a standard protocol from
whole blood obtained from 22 discordant MZ twin pairs (n
¼ 44 individuals) enrolled in the Maudsley Twin Studies of
Bipolar Disorder and Schizophrenia. All subjects underwent
extensive clinical assessment by two psychiatrists and two
psychologists, as detailed previously to confirm discordance
for psychotic illness (52). At the time of blood collection, an
average of 12.6 (+10.6) years had elapsed since the onset
of the illness in the affected twin member (Table 1). Full
demographic data pertaining to each of the samples used in
this study are given in Table 1 and Supplementary Material,
Table S1.
Genome-wide DNA methylation assay
Five hundred nanograms of genomic DNA from each individ-
ual was treated with sodium bisulfite in duplicate, using the EZ
96-DNA methylation kit (Zymo Research, CA, USA), follow-
ing the manufacturer’s standard protocol. Genome-wide DNA
methylation was assessed using the Illumina Infinium Human-
Methylation27 BeadChip (Illumina, Inc., CA, USA), which
interrogates 27 578 CpG sites associated with approximately
14 000 genes. Arrays were processed using a standard protocol
as described elsewhere (53), with both members of a twin pair
being hybridized to the same microarray to control against
batch effects. The Illumina GenomeStudio software was
used to extract the signal intensities of each probe and to
perform initial quality control checks, with all data sets
being considered to be high quality. Probes with a detection
P-value .0.05 in any of the samples were removed across
all individuals (n ¼ 733 probes) to stringently control for
poor-quality probes.
Microarray data analysis
All computations and statistical analyses were performed
within the R statistical analysis environment (http://www.r-p
roject.org), and all analysis scripts are available on request
from the authors. Briefly, signal intensities for each probe
were normalized using quantile normalization to reduce un-
wanted inter-array variation. The relative methylation level
of each interrogated CpG site was calculated as the ratio of
the normalized signal from the methylated probe to the sum
of the normalized signals of the methylated and unmethylated
probes. This gave an average b-value for each CpG site,
ranging from 0 (unmethylated) to 1 (fully methylated). A
density plot of b-values for every sample revealed that, as
expected, the data followed a bimodal distribution. An empir-
ical variance stabilizing transformation was used to account
for the bimodal distribution of the data (Supplementary Mater-
ial, Fig. S8).
We developed an analytical approach that took advantage of
the discordant MZ twin design and incorporated both magni-
tude and significance to maximize our chances of identifying
real within-twin differences in DNA methylation. For the
genome-wide correlation analyses, ‘variable probes’ were
identified by calculating an estimate of the standard deviation
of the whole data set and then filtering out probes that had a
probe-wise standard deviation smaller than the estimated
standard deviation. Our ranking analysis comprised two separ-
ate tests. The first was a standard paired t-test to assess the sig-
nificance of DNA methylation differences between the
affected and unaffected member in each twin pair. The
second assessed the size of methylation differences: a
delta-b (Db) value was calculated representing the mean dif-
ference in methylation between the affected and unaffected
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member in each twin pair (values stated refer to unaffected
minus affected twin). Results from both tests were ranked,
by P-value and size, respectively, and then the two ranked
lists were combined to give a final ranked list of the CpG
sites demonstrating the largest and most consistent differences
in DNA methylation across all twin pairs. To generate statis-
tics based on the magnitude of change observed between
affected and unaffected twins at each locus, we developed a
custom-weighted t-test that adds weight to bigger twin differ-
ences by using a constant standard deviation as the denomin-
ator in the t-test (estimated from array-wide distribution). This
analysis approach was conducted for (i) all twin pairs discord-
ant for major psychosis (n ¼ 22 pairs, 44 individuals), then
separately for (ii) the SZ-discordant twins (n ¼ 11 pairs, 22
individuals) and (iii) the BD-discordant twins (n ¼ 11 pairs,
22 individuals). A summary of our analysis strategy is pre-
sented in Supplementary Material, Figure S9. Furthermore,
given the known phenotypic heterogeneity of both SZ and
BD, we screened for large Db-values within each discordant
MZ twin pair to examine the possibility that disease-associated
epigenetic changes are not consistent across all patients.
Global DNA methylation assay
The heavily methylated, abundant, long interspersed nucleotide
element-1 (LINE-1) is routinely assayed to give a proxy for
global DNAmethylation levels (54).We used the commercially
available Pyrosequencing LINE-1 assay (Qiagen, Hilden,
Germany) and followed the manufacturers’ instructions using
the Pyromark Q24 (Qiagen) platform. DNA from each individ-
ual was treated with sodium bisulfite in duplicate, using the EZ
96-DNAmethylation kit and positive controls—both artificially
methylated and artificially unmethylated sampleswere included
in all experimental procedures to ensure accuracy in quantifica-
tion. LINE-1 methylation was calculated as an average across
the three interrogated CpG sites across both replicates after
bisulfite-PCR-pyrosequencing, and a standard paired t-test
was used to assess the significance of global DNA methylation
differences between the affected and unaffected member in
each twin pair.
Pathway and network analysis
IPA software (version 9.0) (Ingenuity Systems, Redwood City,
CA, USA; www.ingenuity.com) was used to assess the
top-ranked disease-associated, differentially methylated
genes for the enrichment of gene networks, canonical path-
ways and biological processes relevant to the pathogenesis
of psychosis. Lists of the top 100 ranked genes from the ana-
lysis of twin pairs discordant for SZ and twin pairs discordant
for BD were uploaded to IPA and each gene was mapped to its
corresponding gene object in the Ingenuity Knowledge Base
(IKB), a repository of biological interactions and functional
annotations created from millions of individually modeled
relationships between proteins, genes, complexes, cells,
tissues, drugs and diseases (see www.ingenuity.com). Enrich-
ment for specific pathways and biological functions was deter-
mined relative to the IKB database, using a right-tailed
Fisher’s test at a significance level of P, 0.05.
Verification of ST6GALNAC1
For the top-ranked psychosis CpG site, in ST6GALNAC1, we
performed verification analysis using the Sequenom EpiTY-
PER platform. Our assay spanned six CpG sites, including
the specific CpG interrogated on the Illumina 27 K array.
Five hundred nanograms of DNA from each individual (n ¼
22 pairs, 44 individuals) was independently treated with
sodium bisulfite, using the EZ 96-DNA methylation kit.
Bisulfite-PCR amplification was performed in duplicate,
using the primers and assay conditions given in Supplemen-
tary Material, Table S11. Quantitative DNA methylation ana-
lysis was conducted using the Sequenom EpiTYPER system
(Sequenom, Inc., CA, USA), which utilizes base-specific
cleavage followed by MALDI-TOF mass spectrometry (55).
Positive controls, including both artificially methylated and ar-
tificially unmethylated samples, were included in all experi-
mental procedures to ensure accuracy in quantification. A
standard paired t-test was used to assess the significance of
DNA methylation differences between the affected and un-
affected member in each twin pair.
Replication in postmortem brain samples
Forty-five postmortem brain samples were obtained from
the Stanley Medical Neuropathology Consortium (n ¼ 15
SZ, n ¼ 15 BD, n ¼ 15 control) (56). DNA was isolated
using a standard phenol–chloroform extraction method and
bisulfite treated using the EZ 96 DNA methylation kit. DNA
methylation across six CpG sites in the ST6GALNAC1 pro-
moter was assessed using bisulfite-PCR and the Sequenom
EpiTYPER system, as described above.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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